By |

Profile

Oxurion NV is a Belgium based biopharmaceutical company. The company is focused on developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has developed a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. It owns the global rights to Jetrea (ocriplasmin), the pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).

Contact Information

Website: www.oxurion.com
Email: chris.buyse@thrombogenics.com
Main Phone: +32 16751310
Address: Gaston Geenslaan 1
City / Town: Leuven
Country: BEL
Postal Code: B-3001

Issuer Information

Exchange: OTO
Employees: 80


Gathering Data... Please wait

Profile

Oxurion NV is a Belgium based biopharmaceutical company. The company is focused on developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has developed a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. It owns the global rights to Jetrea (ocriplasmin), the pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).

Contact Information

Website: www.oxurion.com
Email: chris.buyse@thrombogenics.com
Main Phone: +32 16751310
Address: Gaston Geenslaan 1
City / Town: Leuven
Country: BEL
Postal Code: B-3001

Issuer Information

Exchange: OTO
Employees: 80
$ 4.10 $ 0. (0.00%)
Last Price 4.10 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close 4.10
Last Trade Volume 0 52 Wk Hi 9.20 52 Wk Low 3.87
Market Cap 156.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 38,271,575.00 EPS (TTM) 0.77 PE Ratio 5.30 Exchange OTCPK